Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2015 Jul 1;25(13):2607-12. doi: 10.1016/j.bmcl.2015.04.090. Epub 2015 May 6.

Recent advances for FLAP inhibitors.

Author information

1
CVMD iMed, AstraZeneca R&D Mölndal, S-413 83 Mölndal, Sweden. Electronic address: daniel.pettersen@astrazeneca.com.
2
CVMD iMed, AstraZeneca R&D Mölndal, S-413 83 Mölndal, Sweden.

Abstract

A number of FLAP inhibitors have been progressed to clinical trials for respiratory and other inflammatory indications but so far no drug has reached the market. With this Digest we assess the opportunity to develop FLAP inhibitors for indications beyond respiratory disease, and in particular for atherosclerotic cardiovascular disease. We also show how recently disclosed FLAP inhibitors have structurally evolved from the first generation FLAP inhibitors paving the way for new compound classes.

KEYWORDS:

5-LO; Cardiovascular; FLAP; Inflammatory; Leukotrienes

PMID:
26004579
DOI:
10.1016/j.bmcl.2015.04.090
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center